Cardiovascular risk in chronic kidney disease: Role of the sympathetic nervous system

Cardiology Research and Practice

Volumn 1, Issue 1, 2012, Pages

  Park, Jeanie ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; RENIN INHIBITOR;

ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTONOMIC NEUROPATHY; BIOACCUMULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HEART STIMULATION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSORY NERVE; SUDDEN DEATH;

EID: 84866252551     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2012/319432     Document Type: Review

References (89)

1. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004 351 13 1296 1305 2-s2.0-4644221457 10.1056/NEJMoa041031
2. Matsushita K., van der Velde M., Astor B. C., Woodward M., Levey A. S., de Jong P. E., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet 2010 375 9731 2073 2081 10.1016/S0140-6736(10)60674-5
3. Rucker D., Tonelli M., Cardiovascular risk and management in chronic kidney disease. Nature Reviews Nephrology 2009 5 5 287 296 2-s2.0-67650376386 10.1038/nrneph.2009.42
4. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003 42 5 1050 1065 2-s2.0-0242441465 10.1161/01.HYP.0000102971. 85504.7c
5. Wen C. P., Cheng T. Y. D., Tsai M. K., Chang Y. C., Chan H. T., Tsai S. P., Chiang P. H., Hsu C. C., Sung P. K., Hsu Y. H., Wen S. F., All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. The Lancet 2008 371 9631 2173 2182 2-s2.0-45949095467 10.1016/S0140-6736(08)60952-6
6. Herzog C. A., Asinger R. W., Berger A. K., Charytan D. M., Díez J., Hart R. G., Eckardt K. U., Kasiske B. L., McCullough P. A., Passman R. S., DeLoach S. S., Pun P. H., Ritz E., Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney International 2011 80 6 572 586 2-s2.0-79960189081 10.1038/ki.2011.223
7. Green D., Roberts P. R., New D. I., Kalra P. A., Sudden cardiac death in hemodialysis patients: an in-depth review. American Journal of Kidney Diseases 2011 57 6 921 929 2-s2.0-79956352144 10.1053/j.ajkd.2011.02.376
8. Sosnov J., Lessard D., Goldberg R. J., Yarzebski J., Gore J. M., Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. American Journal of Kidney Diseases 2006 47 3 378 384 2-s2.0-32844458329 10.1053/j.ajkd.2005.11.017
9. Stenvinkel P., Carrero J. J., Axelsson J., Lindholm B., Heimbürger O., Massy Z., Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clinical Journal of the American Society of Nephrology 2008 3 2 505 521 2-s2.0-42549131781 10.2215/CJN.03670807
10. Grassi G., Quarti-Trevano F., Seravalle G., Arenare F., Volpe M., Furiani S., Delloro R., Mancia G., Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011 57 4 846 851 2-s2.0-79953177793 10.1161/HYPERTENSIONAHA.110.164780
11. Klein I. H. H. T., Ligtenberg G., Neumann J., Oey P. L., Koomans H. A., Blankestijn P. J., Sympathetic nerve activity is inappropriately increased in chronic renal disease. Journal of the American Society of Nephrology 2003 14 12 3239 3244 2-s2.0-0344236401 10.1097/01.ASN.0000098687.01005.A5
12. Joles J. A., Koomans H. A., Causes and consequences of increased sympathetic activity inrenal disease. Hypertension 2004 43 4 699 706 2-s2.0-1642460746 10.1161/01.HYP.0000121881.77212.b1
13. Converse R. L. Jr., Jacobsen T. N., Toto R. D., Jost C. M. T., Cosentino F., Fouad- Tarazi F., Victor R. G., Sympathetic overactivity in patients with chronic renal failure. New England Journal of Medicine 1992 327 27 1912 1918 2-s2.0-0027075024
14. Fisher J. P., Young C. N., Fadel P. J., Central sympathetic overactivity: maladies and mechanisms. Autonomic Neuroscience 2009 148 1-2 5 15 2-s2.0-67349117335 10.1016/j.autneu.2009.02.003
15. Volders P. G. A., Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm 2010 7 12 1900 1906 2-s2.0-78650079155 10.1016/j.hrthm.2010.06.003
16. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F. A., Tripepi G., Bonanno G., Rapisarda F., Fatuzzo P., Seminara G., Cateliotti A., Stancanelli B., Malatino L. S., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002 105 11 1354 1359 2-s2.0-0037133633 10.1161/hc1102.105261
17. Zoccali C., Mallamaci F., Tripepi G., Parlongo S., Cutrupi S., Benedetto F. A., Cataliotti A., Malatino L. S., Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002 40 1 41 46 2-s2.0-0036311224 10.1161/01.HYP.0000022063.50739.60
18. Seals D. R., Dinenno F. A., Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging. American Journal of Physiology 2004 287 5 H1895 H1905 2-s2.0-7244247007 10.1152/ajpheart.00486.2004
19. Grassi G., Seravalle G., Dell'Oro R., Mancia G., Sympathetic mechanisms, organ damage, and antihypertensive treatment. Current Hypertension Reports 2011 13 4 303 308 2-s2.0-79953072137 10.1007/s11906-011-0200-4
20. Amann K., Rump L. C., Simonaviciene A., Oberhauser V., Wessels S., Orth S. R., Gross M. L., Koch A., Bielenberg G. W., Van Kats J. P., Ehmke H., Mall G., Ritz E., Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. Journal of the American Society of Nephrology 2000 11 8 1469 1478 2-s2.0-0033912730
21. Nguyen A. H., Garfinkel A., Walter D. O., Hamilton M. A., Fonarow G. C., Moriguchi J. D., Hage A., Weiss J. N., Middlekauff H. R., Dynamics of muscle sympathetic nerve activity in advanced heart failure patients. American Journal of Physiology 1996 271 5 H1962 H1969 2-s2.0-0029853835
22. Leimbach W. N., Wallin B. G., Victor R. G., Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986 73 5 913 919 2-s2.0-0022591615
23. Fraga R., Franco F. G., Roveda F., de Matos L. N. J., Braga A. M. F. W., Rondon M. U. P. B., Rotta D. R., Brum P. C., Barretto A. C. P., Middlekauff H. R., Negrão C. E., Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. European Journal of Heart Failure 2007 9 6-7 630 636 2-s2.0-34248170301 10.1016/j.ejheart.2007.03.003
24. Patel M. B., Stewart J. M., Loud A. V., Anversa P., Wang J., Fiegel L., Hintze T. H., Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991 84 5 2091 2100 2-s2.0-0025943382
25. Perlini S., Palladini G., Ferrero I., Tozzi R., Fallarini S., Facoetti A., Nano R., Clari F., Busca G., Fogari R., Ferrari A. U., Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005 46 5 1213 1218 2-s2.0-27444436450 10.1161/01.HYP.0000185689.65045.4c
26. Levick S. P., Murray D. B., Janicki J. S., Brower G. L., Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 2010 55 2 270 276 2-s2.0-74949095694 10.1161/ HYPERTENSIONAHA.109.142042
27. Bevan R. D., Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension 1984 6 6 I-19 I-26 2-s2.0-1642410694
28. Failla M., Grappiolo A., Emanuelli G., Vitale G., Fraschini N., Bigoni M., Grieco N., Denti M., Giannattasio C., Mancia G., Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. Journal of Hypertension 1999 17 8 1117 1123 2-s2.0-0032796822 10.1097/00004872-199917080- 00011
29. Bleeke T., Zhang H., Madamanchi N., Patterson C., Faber J. E., Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circulation Research 2004 94 1 37 45 2-s2.0-0346059582 10.1161/01.RES.0000109412.80157.7D
30. Jamerson K. A., Julius S., Gudbrandsson T., Andersson O., Brant D. O., Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993 21 5 618 623 2-s2.0-0027514229
31. Krespi P. G., Makris T. K., Hatzizacharias A. N., Triposkiadis P., Tsoukala C., Kyriaki D., Votteas V., Kyriakidis M., Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovascular Drugs and Therapy 1998 12 5 463 467 2-s2.0-0032410297 10.1023/A:1007702132210
32. Strojek K., Grzeszczak W., Górska J., Leschinger M. I., Ritz E., Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? Journal of the American Society of Nephrology 2001 12 3 602 605 2-s2.0-0035127375
33. Cuche J. L., Prinseau J., Selz F., Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patients. Kidney International 1986 30 4 566 572 2-s2.0-0022450853
34. Elias A. N., Vaziri N. D., Maksy M., Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. Archives of Internal Medicine 1985 145 6 1013 1015 2-s2.0-0021828617 10.1001/archinte.145.6.1013
35. Ligtenberg G., Blankestijn P. J., Oey P. L., Klein I. H. H., Dijkhorst-Oei L. T., Boomsma F., Wieneke G. H., Van Huffelen A. C., Koomans H. A., Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. New England Journal of Medicine 1999 340 17 1321 1328 2-s2.0-0033614449 10.1056/NEJM199904293401704
36. Park J., Campese V. M., Middlekauff H. R., Exercise pressor reflex in humans with end-stage renal disease. American Journal of Physiology 2008 295 4 R1188 R1194 2-s2.0-57349100795 10.1152/ajpregu.90473.2008
37. Park J., Campese V. M., Nobakht N., Middlekauff H. R., Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. Journal of Applied Physiology 2008 105 6 1873 1876 2-s2.0-57349187739 10.1152/japplphysiol.90849.2008
38. Klein I. H. H. T., Ligtenberg G., Oey P. L., Koomans H. A., Blankestijn P. J., Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. Journal of the American Society of Nephrology 2003 14 2 425 430 2-s2.0-0037304676 10.1097/01.ASN.0000045049.72965.B7
39. Campese V. M., Kogosov E., Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995 25 4 878 882 2-s2.0-0028953330
40. Campese V. M., Kogosov E., Koss M., Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. American Journal of Kidney Diseases 1995 26 5 861 865 2-s2.0-0028858468
41. Ye S., Ozgur B., Campese V. M., Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney International 1997 51 3 722 727 2-s2.0-0030991661
42. Ye S., Zhong H., Campese V. M., Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 2006 48 2 309 315 2-s2.0-33748169328 10.1161/01.HYP.0000231307. 69761.2e
43. Ye S., Zhong H., Yanamadala V., Campese V. M., Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. American Journal of Hypertension 2002 15 8 717 724 2-s2.0-0035997360 10.1016/S0895-7061(02)02959-X
44. Klein I. H. H. T., Ligtenberg G., Oey P. L., Koomans H. A., Blankestijn P. J., Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. Journal of the American Society of Nephrology 2001 12 11 2427 2433 2-s2.0-0034758803
45. Campese V. M., Ku E., Park J., Sympathetic renal innervation and resistant hypertension. International Journal of Hypertension 2011 2011 814354
46. Hausberg M., Kosch M., Harmelink P., Barenbrock M., Hohage H., Kisters K., Dietl K. H., Rahn K. H., Sympathetic nerve activity in end-stage renal disease. Circulation 2002 106 15 1974 1979 2-s2.0-0037044429 10.1161/01.CIR.0000034043.16664.96
47. Katholi R. E., Whitlow P. L., Hageman G. R., Woods W. T., Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. Journal of Hypertension 1984 2 4 349 359 2-s2.0-0021172352
48. Bergamaschi C. T., Campos R. R., Lopes O. U., Rostral ventrolateral medulla: a source of sympathetic activation in rats subjected to long-term treatment with L-NAME. Hypertension 1999 34 4 744 747 2-s2.0-0032752709
49. Sander M., Chavoshan B., Victor R. G., A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999 33 4 937 942 2-s2.0-0032916427
50. Sander M., Victor R. G., Neural mechanisms in nitric-oxide-deficient hypertension. Current Opinion in Nephrology and Hypertension 1999 8 1 61 73 10.1097/00041552-199901000-00011
51. Grassi G., Seravalle G., Ghiadoni L., Tripepi G., Bruno R. M., Mancia G.,. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2011 6 11 2620 2627 10.2215/CJN.06970711
52. Ueda S., Yamagishi S. I., Matsumoto Y., Fukami K., Okuda S., Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clinical and Experimental Nephrology 2007 11 2 115 121 2-s2.0-34347323965 10.1007/s10157-007-0471-x
53. Vallance P., Leone A., Calver A., Collier J., Moncada S., Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. The Lancet 1992 339 8793 572 575 2-s2.0-0026548912 10.1016/0140-6736(92)90865-Z
54. Zoccali C., Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney International 2006 70 12 2053 2055 2-s2.0-33845331757 10.1038/sj.ki.5001898
55. Zoccali C., Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. Journal of Hypertension 2006 24 4 611 619 2-s2.0-33645517326 10.1097/01.hjh.0000217839.26971.8d
56. Mallamaci F., Tripepi G., Maas R., Malatino L., Böger R., Zoccali C., Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology 2004 15 2 435 441 2-s2.0-0942298015 10.1097/01.ASN.0000106717.58091.F6
57. Böger R. H., Zoccali C., ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis Supplements 2003 4 4 23 28 2-s2.0-1242273853 10.1016/S1567-5688(03)00030-8
58. Augustyniak R. A., Victor R. G., Morgan D. A., Zhang W., L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. American Journal of Physiology 2006 290 3 R726 R732 2-s2.0-33645407190 10.1152/ajpregu.00768.2004
59. Zoccali C., Mallamaci F., Maas R., Benedetto F. A., Tripepi G., Malatino L. S., Cataliotti A., Bellanuova I., Böger R., Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney International 2002 62 1 339 345 2-s2.0-0036315607 10.1046/j.1523-1755.2002.00437.x
60. Zoccali C., Benedetto F. A., Maas R., Mallamaci F., Tripepi G., Malatino L. S., Böger R., Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. Journal of the American Society of Nephrology 2002 13 2 490 496 2-s2.0-0036156916
61. Zoccali C., Bode-Böger S. M., Mallamaci F., Benedetto F. A., Tripepi G., Malatino L. S., Cataliotti A., Bellanuova I., Fermo I., Frölich J. C., Böger R. H., Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. The Lancet 2001 358 9299 2113 2117 2-s2.0-0035936406 10.1016/S0140-6736(01)07217-8
62. Cottone S., Lorito M. C., Riccobene R., Nardi E., Mulè G., Buscemi S., Geraci C., Guarneri M., Arsena R., Cerasola G., Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. Journal of Nephrology 2008 21 2 175 179 2-s2.0-50049130554
63. Shah S. V., Baliga R., Rajapurkar M., Fonseca V. A., Oxidants in chronic kidney disease. Journal of the American Society of Nephrology 2007 18 1 16 28 2-s2.0-33845991537 10.1681/ASN.2006050500
64. Schiffrin E. L., Lipman M. L., Mann J. F. E., Chronic kidney disease: effects on the cardiovascular system. Circulation 2007 116 1 85 97 2-s2.0-34347350171 10.1161/CIRCULATIONAHA.106.678342
65. Campese V. M., Ye S., Zhong H., Yanamadala V., Ye Z., Chiu J., Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. American Journal of Physiology 2004 287 2 H695 H703 2-s2.0-3242675168 10.1152/ajpheart.00619.2003
66. Hirooka Y., Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertension Research 2011 34 4 407 412 2-s2.0-79953691140 10.1038/hr.2011.14
67. Fujita M., Ando K., Nagae A., Fujita T., Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension. Hypertension 2007 50 2 360 367 2-s2.0-34547630857 10.1161/HYPERTENSIONAHA.107.091009
68. Oliveira-Sales E. B., Dugaich A. P., Carillo B. A., Abreu N. P., Boim M. A., Martins P. J., D'Almeida V., Dolnikoff M. S., Bergamaschi C. T., Campos R. R., Oxidative stress contributes to renovascular hypertension. American Journal of Hypertension 2008 21 1 98 104 2-s2.0-38349129598 10.1038/ajh.2007.12
69. Fujita M., Ando K., Kawarazaki H., Kawarasaki C., Muraoka K., Ohtsu H., Sympathoexcitation by brain oxidative stress mediates arterial pressure elevation in salt-induced chronic kidney disease. Hypertension 2012 59 1 105 112 10.1161/HYPERTENSIONAHA.111.182923
70. Macarthur H., Westfall T. C., Wilken G. H., Oxidative stress attenuates NO-induced modulation of sympathetic neurotransmission in the mesenteric arterial bed of spontaneously hypertensive rats. American Journal of Physiology 2008 294 1 H183 H189 2-s2.0-38149091417 10.1152/ajpheart.01040.2007
71. Reid I. A., Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. American Journal of Physiology 1992 262 6 E763 E778 2-s2.0-0026719883
72. Matsukawa T., Gotoh E., Minamisawa K., Kihara M., Ueda S. I., Shionoiri H., Ishii M., Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. American Journal of Physiology 1991 261 3 R690 R696 2-s2.0-0025942184
73. Siddiqi L., Oey P. L., Blankestijn P. J., Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrology Dialysis Transplantation 2011 26 9 2930 2934 10.1093/ndt/gfq857
74. Tangri N., Shastri S., Tighiouart H., Beck G. J., Cheung A. K., Eknoyan G., beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. American Journal of Kidney Diseases 2011 58 6 939 945 10.1053/j.ajkd.2011.06.024
75. Bakris G. L., Hart P., Ritz E., Beta blockers in the management of chronic kidney disease. Kidney International 2006 70 11 1905 1913 2-s2.0-33845267499 10.1038/sj.ki.5001835
76. Siddiqi L., Joles J. A., Oey P. L., Blankestijn P. J., Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. Journal of Hypertension 2011 29 11 2176 2180 10.1097/HJH.0b013e32834ae3c7
77. Zilch O., Vos P. F., Oey P. L., Cramer M. J. M., Ligtenberg G., Koomans H. A., Blankestijn P. J., Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. Journal of Hypertension 2007 25 6 1285 1289 2-s2.0-34250308341 10.1097/HJH.0b013e3280f9df85
78. Friedman O., Bradley T. D., Chan C. T., Parkes R., Logan A. G., Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010 56 6 1077 1082 2-s2.0-78650416887 10.1161/HYPERTENSIONAHA.110.154427
79. Dudenbostel T., Calhoun D. A., Resistant hypertension, obstructive sleep apnoea and aldosterone. Journal of Human Hypertension 2012 26 5 281 287 2-s2.0-79958034683 10.1038/jhh.2011.47
80. Grassi G., Facchini A., Trevano F. Q., Dell'Oro R., Arenare F., Tana F., Bolla G., Monzani A., Robuschi M., Mancia G., Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005 46 2 321 325 2-s2.0-23244437764 10.1161/01.HYP.0000174243.39897.6c
81. Narkiewicz K., Van De Borne P. J. H., Cooley R. L., Dyken M. E., Somers V. K., Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998 98 8 772 776 2-s2.0-0032566399
82. Narkiewicz K., Van De Borne P. J. H., Montano N., Dyken M. E., Phillips B. G., Somers V. K., Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998 97 10 943 945 2-s2.0-0032539896
83. Abdel-Kader K., Dohar S., Shah N., Jhamb M., Reis S. E., Strollo P., Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. Journal of Hypertension 2012 30 5 960 966 10.1097/HJH.0b013e328351d08a
84. Esler M. D., Krum H., Sobotka P. A., Schlaich M. P., Schmieder R. E., Böhm M., Mahfoud F., Sievert H., Wunderlich N., Rump L. C., Vonend O., Uder M., Lobo M., Caulfield M., Erglis A., Azizi M., Sapoval M., Thambar S., Persu A., Renkin J., Schunkert H., Weil J., Hoppe U. C., Walton T., Scheinert D., Binder T., Januszewicz A., Witkowski A., Ruilope L. M., Whitbourn R., Bruck H., Downes M., Lüscher T. F., Jardine A. G., Webster M. W., Zeller T., Sadowski J., Bartus K., Straley C. A., Barman N. C., Lee D. P., Witteles R. M., Bhalla V., Massaro J. M., Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet 2010 376 9756 1903 1909 2-s2.0-78649876825 10.1016/S0140-6736(10)62039-9
85. Schlaich M. P., Hering D., Sobotka P., Krum H., Lambert G. W., Lambert E., Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Frontiers in Physiology 2012 3, artilce 10
86. Schlaich M. P., Sobotka P. A., Krum H., Lambert E., Esler M. D., Renal sympathetic-nerve ablation for uncontrolled hypertension. New England Journal of Medicine 2009 361 9 932 934 2-s2.0-69349085170 10.1056/NEJMc0904179
87. Grassi G., Dell'Oro R., Seravalle G., Foglia G., Trevano F. Q., Mancia G., Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 2002 106 15 1957 1961 2-s2.0-0037044420 10.1161/01.CIR.0000033519.45615.C7
88. Roveda F., Middlekauff H. R., Rondon M. U. P. B., Reis S. F., Souza M., Nastari L., Barretto A. C. P., Krieger E. M., Negrão C. E., The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. Journal of the American College of Cardiology 2003 42 5 854 860 2-s2.0-0041876236 10.1016/S0735-1097(03)00831-3
89. Pergola P. E., Raskin P., Toto R. D., Meyer C. J., Huff J. W., Grossman E. B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D. G., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. New England Journal of Medicine 2011 365 4 327 336 2-s2.0-79960855656 10.1056/NEJMoa1105351